RE: A great deal! Yes, we all feel your angst Jentai. But without PMI's tobacco plants, their continuing investment capital support, all their US government connections, building Medicago's first manufacturing facility for them in NC, PMI's huge well established reach in 180 countries, including global marketing clout and expertise, how far along do you think Medicago would be today trying to develop their products just in Canada on their own?.
It seems to me that these license agreements with PMP is a big mutual 'win win' for all parties. It takes a load off Medicago, letting PMP do all the heavy lifting of manfacturing and marketing in China. Meanwhile Medicago gets upfront, and development payments totalling $12M and can also sit back getting royalty payments for all future vaccines sold in China with the biggest population in the world. In contrast, Medicago for a one time payment of $700k, gets to license a portfolio of plant-based protein development technologies from PMP. These technologies include tools and methods for producing proteins in plants which are expected to complement Medicago's existing patent portfolio.
All in all, with more development dollars and future royalty revenue stream income coming in, it let's Medicago get on with the business of contining to focus on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles.
If you think India is next, then I say 'bring it on!'